The efficacy and safety of Health One has been our top priority since Day 1. To that end, HNT has taken every opportunity to participate in clinical studies. The following is a partial list of studies using Health One.
Research Using Health One
Click on a title below to see more information about the research project.
Carney, D. et al. (2015). Successful Medical Weight Loss in a Community Setting. J Obes Weight Loss Ther. 5(1): 248.
This large clinical data set, 714 patients over an 8 year period, includes post-treatment follow-up weights demonstrating long-term efficacy for community delivered medical weight management. Follow up weights obtained from 173 patients more than 2 years after treatment ended showed persisting weight loss of 14.3 ± 13.7 kg and 12.9%.
HEADS UP Study- Pennington Biomedical Research Center, (2014- ongoing).
Heads Up is an observational trial studying obesity management best practices in a state employee health insurance group. The study will look at the effects of an intensive medical intervention on weight loss, total medical costs, and measures of health risks associated with weight loss (blood pressure, blood glucose, blood lipids, and health-related quality of life). One arm uses Health One meal replacements in conjunction with behavior change support, the other arm uses bariatric surgery.
Ryan, D, et al. (2010). Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings. Arch Intern Med. 170(2):146-154.
LOSS STUDY: The State of Louisiana, through the State Office of Group Benefits, tested a variety of treatment protocols for weight management for efficacy to lower body weight, improve health parameters, and serve as a cost-saving approach, both for the individual and for the third party payer. This study started in July, 2005. The study used HEALTH ONE plus “intensive counseling” as one of the treatment arms. The principal investigator was Dr. Donna Ryan from the Pennington Biomedical Research Institute (which is affiliated with Louisiana State University Medical Center).
de Jonge L, Moreira E AM, Martin CK, Ravussin E. (2010) Impact of six-month caloric restriction on autonomic nervous system activity in healthy, overweight individuals. Obesity 18: 414-416.
This study explored the effects of calorie restriction on the relative function of the sympathetic nervous system, and the parasympathetic nervous system, an independent risk factor of cardiovascular disease.
Noe, M. A., et al. (2010). The Health Improvement Project (HIP): A Report on the Outcome of an Intensive Medical Intervention for Class III Obesity. Obesity 18(2):148.
HIP STUDY : A study similar to the one described immediately below started in 2005 and discontinued after 24 months at the University of Buffalo, Center for Preventive Medicine. This study was underwritten by Blue Cross and Blue Shield of New York. Results presented in a poster session at The Obesity Society annual meeting in 2010.
Greenway, F., Tomayko, K., et al. BARIA Study. (Initiated September 2009). Comparison of longer term outcomes of weight loss between use of low calorie meal replacement (HEALTH ONE) and bariatric surgical techniques. Pennington Center For Biomedical Research, Baton Rouge, LA.
Carney, D., Schultz, S., Carney, S. (2009). Medical Obesity Treatment: Long-Term Success in a Primary Care Setting. J Diabetes Sci. Technol. 3(6):1524-6.
This publication detailed clinical results from 917 patients on an HNT weight management program from 1991 to 2004. Weight loss was 16% ± 8.4% (17.5 ± 10.7 kg) after 14.2 weeks. After 11.9 months in maintenance, weight loss was still 16.4% ± 8.7% (18.4 ± 11.4 kg).
Williamson, D.A., Rejeski, J., Lang, W., Van Dorsten, B., Fabricatore, A.N., Toledo, K. (2009). Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Archives of Internal Medicine 169: 163-171.
This publication resulted from work done by the “Look AHEAD” research group at the Pennington Center For Biomedical Research. Look AHEAD is a 16-center randomized clinical trial in overweight and obese patients with type 2 diabetes designed to evaluate the long-term effects of an intensive weight loss intervention on health-related quality of life outcomes (physical and mental) from weight intervention such as cardiovascular disease and depression.
Larson-Meyer DE, Redman LM, Heilbronn LK, Martin CK, Ravussin E. (2009). Calorie Restriction with or without exercise: The Fitness vs. Fatness Debate. Med Sci Sports Exerc. Dec. 152-159.
This study investigated the difference in cardiometabolic benefits between a 25% energy deficit from calorie restriction that produces equal change in body fatness with and without aerobic exercise.
Anton SD, Martin CK, Redman L, York-Crowe E, Heilbronn LK, Han H, Williamson DA. (2008). Ravussin E: psychosocial and behavioral pre-treatment predictors of weight loss outcomes. Eat Weight Disord; March; 13:30-37.
Heilbronn, L.K., de Jonge, et al. (2006). Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA 295:1539-1548.
This study is sponsored by the National Institute of Aging and is designed to examine whether calorie restriction will increase lifespan in humans as it does in worms and rodents. This study is divided into 4 groups of 15 subjects with an initial BMI of 25-30 kg/m2: a control group, a group in which calories are restricted by 25%, a group in which calories are restricted by 12.5% and energy expenditure is increased by 12.5%, and a group in which weight is reduced by 15% using Health-1 and maintained with calorie restriction. The 6-month study has been completed and the manuscript has been submitted for publication. The control group lost 1% of body weight (NS), the calorie restriction group lost 10% of body weight, the calorie restriction/exercise group lost 10% of body weight and the Health-1 group lost 13.5% of their body weight at the end of the study. The two calorie restriction groups still had a decreasing weight at the end of the study, but the Health-1 and control groups were maintaining their weight. All three weight loss groups (including Health-1) decreased resting metabolic rate 6% below predicted and the core body temperature dropped compared to the control group. This is consistent with a reduction of oxidative stress, and is similar to what is seen in rodents with calorie restriction.
Richard, B., Asnani, S., Desouza ,C., & Fonseca,V. (2003). Is Weight Gain Inevitable With Thiazolidinediones? Experience With Very Low Calorie Diets. Curr Med Res Opin. Tulane University, New Orleans, LA: Vol 19 (7):609-613.
Patients treated with TZD for type 2 diabetes usually gain weight. 8 type 2 diabetic patients on a variety of medications (including TZD’s) all reported weight gain (above their underlying obesity). These patients were given a low-calorie meal replacement of 800 calories per day (HEALTH ONE) and a mean weight loss of 26 pounds was attained during a 12 week period. Most discontinued or reduced their use of medications (including insulin) and gained glycemic control.
Drab, D., Greenway, F. et. al. (2001). Motivation And Weight Management: A Correlational Study. Psychol. Assess., 13 (2): 189-198.
Greenway, F., Ryan, D., Bray G., et al. (1999). Pharmaceutical Cost Savings Of Treating Obesity With Weight Loss Medications; Pennington Biomedical Research Center, Louisiana State University. Obesity Research, 7(6):523-531.
Used a variety of anorectic/thermogenic weight loss medications (along with the HEALTH ONE Supplement) to attain a 20 pound weight loss with Type II Diabetics. Concluded that considerable cost savings were attained with reduction of medications used to control blood sugar. Also, attributed the health status improvement and cost savings to weight loss and not to any specific medication regimen employed.
Greenway, F. (1999). Obesity Medications And The Treatment Of Type 2 Diabetes. Diabetes Technology & Therapeutics, 1(3): 277-287.
Major review of medications used in the treatment of obesity and obesity related Type 2 Diabetes. Concludes that weight loss formulas of 800 cal/d are far more efficacious for initial weight loss and metabolic control; medications are best utilized in maintaining weight loss.
Henry, R., Medallier, S. Metabolic Effect Of Weight Loss On Glucose Metabolism And Insulin Action In Skeletal Muscle And Adipose Tissue Of Obese Type-2 Diabetics And Non-Diabetics; UC San Diego VA-Medical Center. Unpublished Results*
SPECIFIC AIMS: To determine in vivo and in vitro metabolic effects of weight loss on glucose metabolism and insulin action in skeletal muscle and adipose tissue in obese non-diabetic and type-2 diabetic subjects
